Compare Charles River Laboratories Intl. Inc (CRL) vs Invesco DB Oil Fund (DBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Invesco DB Oil Fund — how do they compare? Charles River Laboratories Intl. Inc trades at $303.31 (market cap $14.23B), while Invesco DB Oil Fund trades at $24.21 (market cap $255.13M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 55.8× Invesco DB Oil Fund's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Invesco DB Oil Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Invesco DB Oil Fund for 31 Days on average.
| CRL | DBO | |
|---|---|---|
Market Cap | $14.23B | $255.13M |
Volume | 1,176,885 | 562,167 |
Sector | Health | Commodities - Energy |
52-Week High | $310.77 | $26.35 |
52-Week Low | $149.93 | $11.98 |
Typical Hold Time | 33 Days | 31 Days |
Enterprise Value | $17.06B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
DBO trades at $23.54, down 0.42% on the day, with technical indicators showing a neutral to bearish bias. The stock faces resistance at $24 and support at $23, while moving averages signal bearish momentum. Recent oil market developments, including Middle East tensions and OPEC+ production decisions, create a volatile backdrop for energy stocks.
The outlook remains cautious given geopolitical risks and mixed oil price signals. Investment opportunities exist if supply disruptions persist, but risks include potential price declines from strategic reserve releases and ongoing legal challenges facing the oil industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Invesco DB Oil Fund
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →
